@article{article, title  = {{SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{http://dx.doi.org/10.1200/jco.2024.42.16_suppl.tps4623 }},

 year = {{2024}},

 month = {{6}},

 author = {{Hussain SA and Loriot Y and de Velasco G and Necchi A}},

 doi = {{10.1200/jco.2024.42.16_suppl.tps4623}},

 volume = {{42}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{16_suppl}},

 pages = {{TPS4623-TPS4623}},

 note = {{Accessed on 2024/12/22}}}